The estimated Net Worth of Ventures Fund Iv General Pa... is at least $308 mil dollars as of 27 May 2022. Ventures Pa owns over 27,397,259 units of Evelo Biosciences Inc stock worth over $308,219 and over the last 2 years Ventures sold EVLO stock worth over $0.
Ventures has made over 1 trades of the Evelo Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Ventures bought 27,397,259 units of EVLO stock worth $39,999,998 on 27 May 2022.
The largest trade Ventures's ever made was buying 27,397,259 units of Evelo Biosciences Inc stock on 27 May 2022 worth over $39,999,998. On average, Ventures trades about 27,397,259 units every 0 days since 2022. As of 27 May 2022 Ventures still owns at least 13,698,630 units of Evelo Biosciences Inc stock.
You can see the complete history of Ventures Pa stock trades at the bottom of the page.
Over the last 7 years, insiders at Evelo Biosciences Inc have traded over $41,656 worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth $81,620,674 . The most active insiders traders include Ventures Fund Iv General Pa..., Noubar Afeyan, eVentures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $19,676. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth $149.
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Evelo Biosciences Inc executives and other stock owners filed with the SEC include: